Giuseppe L.
- Country
- Italy
- Department
- SC Oncologia Medica 1
Research Overview
- Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
- A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
Data & Insights
Has run more than one trial at 407 of 655 partner sites.
Specializations
Thoracic Oncology
Clinical research in non-small cell lung cancer and small cell lung cancer spans advanced, metastatic, and treatment-resistant disease, with attention to molecularly defined subgroups such as EGFR, ALK, ROS1, RET, KRAS G12C, and HER2-altered tumors. The portfolio also includes head and neck squamous cell carcinoma, esophageal carcinoma, and selected thoracic tumors.
- Advanced and metastatic non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Molecularly selected thoracic malignancies
Therapeutic interests include immunotherapy, targeted therapy, and combined systemic approaches for lung and upper aerodigestive tract cancers.
Breast and Gynecologic Malignancies
Work in breast cancer covers triple-negative breast cancer, HER2-positive, HER2-low, and hormone receptor-positive disease across early, locally advanced, and metastatic settings. Ovarian cancer, endometrial cancer, cervical cancer, and gastroesophageal junction adenocarcinoma also appear prominently within the investigator’s gynecologic and upper gastrointestinal research landscape.
- Triple-negative breast cancer
- HER2-positive and HER2-low breast cancer
- Advanced ovarian cancer
- Endometrial and cervical cancer
The therapeutic focus includes antibody-based treatment, checkpoint inhibition, and biomarker-driven strategies in solid tumors.
Genitourinary and Digestive System Cancers
Research activity extends across renal cell carcinoma, urothelial carcinoma, and prostate cancer, alongside a broad digestive oncology portfolio that includes colorectal cancer, gastric cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, and hepatocellular carcinoma. Neuroendocrine tumors and gastrointestinal stromal tumor are also represented.
- Renal cell carcinoma
- Urothelial carcinoma
- Colorectal cancer
- Gastric, pancreatic, and biliary tract cancers
Therapeutic interests include precision oncology, immuno-oncology, and treatment approaches for advanced gastrointestinal and genitourinary malignancies.
Hematologic Malignancies
Clinical trial involvement includes diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, classical Hodgkin lymphoma, and chronic lymphocytic leukemia. The investigator also works in multiple myeloma and other relapsed or refractory blood cancers.
- Diffuse large B-cell lymphoma
- Peripheral T-cell lymphoma
- Classical Hodgkin lymphoma
- Multiple myeloma
The therapeutic emphasis is on cellular therapy, bispecific antibodies, and immune-based treatment in difficult-to-treat hematologic disease.
Neuro-Oncology and Neuromuscular Disorders
Research interests include glioblastoma, glioma, medulloblastoma, ependymoma, atypical teratoid/rhabdoid tumor, neuroblastoma, and high-grade glioma. The portfolio also includes myasthenia gravis, multiple sclerosis, epilepsy, migraine, and selected neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease.
- Glioblastoma and other brain tumors
- Myasthenia gravis
- Multiple sclerosis
- Epilepsy and migraine
Therapeutic activity includes neuro-oncology, autoimmune neurology, and pediatric and adult neurologic disease management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.